Stoke director granted 17,786 stock options
Stoke Therapeutics director Seth Loring Harrison received a grant of 17,786 stock options.
Rhea-AI Filing Summary
Stoke Therapeutics director Seth Loring Harrison received a grant of 17,786 stock options. These Director Stock Options give him the right to buy 17,786 shares of common stock at an exercise price of $29.46 per share and are held directly.
The options vest in full on the earlier of June 3, 2027 or the date of Stoke Therapeutics’ next annual stockholder meeting, as long as he continues serving the company through that vesting date. The options expire on June 2, 2036, and this grant represents his full reported option position in this filing. This is a compensation award, not an open‑market stock purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 17,786 shares
Grant/Award
1 txn
Insider
Harrison Seth Loring
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 17,786 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 17,786 contracts (Direct)
Footnotes (1)
- F1. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Key Figures
Option grant size: 17,786 options
Exercise price: $29.46 per share
Underlying shares: 17,786 shares
+3 more
6 metrics
Option grant size
17,786 options
Director stock option grant on June 3, 2026
Exercise price
$29.46 per share
Exercise price of director stock options
Underlying shares
17,786 shares
Common stock underlying the options
Post-grant option holdings
17,786 options
Total options held following transaction
Vesting date trigger
Earlier of June 3, 2027 or next annual meeting
Vesting condition, subject to continued service
Option expiration
June 2, 2036
Expiration date of director stock options
Key Terms
Director Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more
5 terms
Director Stock Option (Right to Buy) financial
"security_title: Director Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price set at 29.4600 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date listed as 2036-06-02 for the option"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The option shall vest in full on the earlier of June 3, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
FAQ
What did Stoke Therapeutics (STOK) director Seth Loring Harrison receive in this Form 4?
He received a grant of 17,786 director stock options. These options allow him to buy Stoke Therapeutics common stock at a fixed exercise price as part of his director compensation, rather than through an open-market transaction.
What is the exercise price of the new Stoke Therapeutics (STOK) director options?
The options have an exercise price of $29.46 per share. This means Harrison can purchase Stoke Therapeutics common stock at $29.46 once the options vest, regardless of the market price at that time.
When do Seth Loring Harrison’s Stoke Therapeutics (STOK) options vest?
The options vest in full on the earlier of June 3, 2027 or the date of the company’s next annual stockholder meeting. Vesting also requires his continued service to Stoke Therapeutics through the applicable vesting date.
When do the Stoke Therapeutics (STOK) director stock options granted in this Form 4 expire?
These director stock options expire on June 2, 2036. After that expiration date, Harrison will no longer be able to exercise the options to purchase Stoke Therapeutics common shares at the stated exercise price.
Did this Stoke Therapeutics (STOK) Form 4 involve any open-market stock purchases or sales?
No, the filing shows a grant of stock options as compensation, coded as a grant or award. It does not report any open-market buying or selling of Stoke Therapeutics common shares by the director.
How many Stoke Therapeutics (STOK) options does the director hold after this grant?
After the reported grant, Harrison holds 17,786 stock options in total according to the filing. These options are held directly and relate to an equal number of underlying Stoke Therapeutics common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
